ELVN (Enliven Therapeutics) Total Liabilities: $15.07 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ELVN Enliven Therapeutics Inc ELVN
31 GF Score
Price $57.89
! 3 Warning Signs
View Full Analysis

What is Enliven Therapeutics Total Liabilities?

Enliven Therapeutics ELVN -1.43% 31 Total Liabilities is $15.07 Mil as of Jun. 2026. GuruFocus rates ELVN with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

Enliven Therapeutics's Total Liabilities for the quarter that ended in Jun. 2026 was $15.07 Mil.

Enliven Therapeutics's quarterly Total Liabilities declined from Dec. 2025 ($16.57 Mil) to Mar. 2026 ($11.49 Mil) but then increased from Mar. 2026 ($11.49 Mil) to Jun. 2026 ($15.07 Mil).

Enliven Therapeutics's annual Total Liabilities declined from Dec. 2023 ($25.96 Mil) to Dec. 2024 ($15.92 Mil) but then increased from Dec. 2024 ($15.92 Mil) to Dec. 2025 ($16.57 Mil).

Enliven Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Enliven Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enliven Therapeutics Total Liabilities Chart

Enliven Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 156.22 160.12 25.96 15.92 16.57

Enliven Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.42 14.75 16.57 11.49 15.07
ELVN
31GF Score
Enliven Therapeutics Inc ELVN
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enliven Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Enliven Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=16.568+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=16.57

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=476.168-459.6
=16.57

Enliven Therapeutics's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=14.161+(0+0.913
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=15.07

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=910.223-895.149
=15.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $15.07 Mil mean?
Enliven Therapeutics (ELVN) has a Total Liabilities of $15.07 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Enliven Therapeutics and its competitors.
Is Enliven Therapeutics' Total Liabilities too high?
Enliven Therapeutics' current Total Liabilities is $15.07 Mil. Overall, Enliven Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Enliven Therapeutics' Total Liabilities compare to PBLS and CPRX?
Enliven Therapeutics' Total Liabilities of $15.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Enliven Therapeutics and its competitors. Enliven Therapeutics's current Total Liabilities is $15.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enliven Therapeutics stock overvalued right now?
Enliven Therapeutics (ELVN) has a current Total Liabilities of $15.07 Mil. The current Total Liabilities is $15.07 Mil. Enliven Therapeutics' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Enliven Therapeutics (ELVN), the current Total Liabilities is $15.07 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enliven Therapeutics Business Description

Address 6200 Lookout Road, Boulder, CO, USA, 80301
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
31GF Score

Get the complete analysis for ELVN

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$57.89
Price